Evan J. Lipson
Evan J. Lipson
Associate Professor of Oncology, Johns Hopkins University
E-mail megerősítve itt: jhmi.edu - Kezdőlap
Hivatkozott rá
Hivatkozott rá
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ...
Journal of clinical oncology 32 (10), 1020, 2014
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ...
New England Journal of Medicine 374 (26), 2542-2552, 2016
Evolutionary dynamics of cancer in response to targeted combination therapy
I Bozic, JG Reiter, B Allen, T Antal, K Chatterjee, P Shah, YS Moon, ...
elife 2, e00747, 2013
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ...
Clinical Cancer Research 19 (2), 462-468, 2013
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
CG Drake, EJ Lipson, JR Brahmer
Nature reviews Clinical oncology 11 (1), 24-37, 2014
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma
EJ Lipson, CG Drake
Clinical cancer research 17 (22), 6958-6962, 2011
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
L Heinzerling, PA Ott, FS Hodi, AN Husain, A Tajmir-Riahi, H Tawbi, ...
Journal for immunotherapy of cancer 4 (1), 1-11, 2016
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
FB Cortazar, KA Marrone, ML Troxell, KM Ralto, MP Hoenig, JR Brahmer, ...
Kidney international 90 (3), 638-647, 2016
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival
EJ Lipson, JG Vincent, M Loyo, LT Kagohara, BS Luber, H Wang, H Xu, ...
Cancer immunology research 1 (1), 54-63, 2013
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
LC Cappelli, AK Gutierrez, AN Baer, J Albayda, RL Manno, U Haque, ...
Annals of the rheumatic diseases 76 (1), 43-50, 2017
Antagonists of PD-1 and PD-L1 in cancer treatment
EJ Lipson, PM Forde, HJ Hammers, LA Emens, JM Taube, SL Topalian
Seminars in oncology 42 (4), 587-600, 2015
Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer
TJ Williams, DR Benavides, KA Patrice, JO Dalmau, ALR De Ávila, DT Le, ...
JAMA neurology 73 (8), 928-933, 2016
Tumor regression and allograft rejection after administration of anti–PD-1
EJ Lipson, SM Bagnasco, J Moore Jr, S Jang, MJ Patel, AA Zachary, ...
The New England journal of medicine 374 (9), 896, 2016
Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
P Nghiem, S Bhatia, EJ Lipson, WH Sharfman, RR Kudchadkar, AS Brohl, ...
Journal of Clinical Oncology 37 (9), 693, 2019
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
EJ Lipson, VE Velculescu, TS Pritchard, M Sausen, DM Pardoll, ...
Journal for immunotherapy of cancer 2 (1), 1-7, 2014
Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma
L Chen, J Douglass, L Kleinberg, X Ye, AE Marciscano, PM Forde, ...
International Journal of Radiation Oncology* Biology* Physics 100 (4), 916-925, 2018
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1 …
PA Ascierto, I Melero, S Bhatia, P Bono, RE Sanborn, EJ Lipson, ...
Journal of Clinical Oncology 35 (15_suppl), 9520-9520, 2017
Nivolumab: targeting PD-1 to bolster antitumor immunity
JR Brahmer, H Hammers, EJ Lipson
Future oncology 11 (9), 1307-1326, 2015
Cardiovascular toxicities associated with immune checkpoint inhibitors
JR Hu, R Florido, EJ Lipson, J Naidoo, R Ardehali, CG Tocchetti, AR Lyon, ...
Cardiovascular research 115 (5), 854-868, 2019
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20